期刊文献+

BLT2拮抗剂的体外抗肿瘤效应

In vitro anti-tumor effect of BLT2 receptor antagonist LY255283
下载PDF
导出
摘要 目的:探讨白三烯B4受体BLT2拮抗剂LY255283对培养肿瘤细胞增殖的抑制作用。方法:RT-PCR法检测9种人源肿瘤细胞(SMMC7721、A549、Bel7402、BGC823、Eca109、HeLa、HL60、MCF7和Pc3细胞)中BLT2的表达情况;MTT法分析LY255283对上述体外培养肿瘤细胞的增殖抑制作用;流式细胞术及荧光显微镜分析LY255283对MCF7细胞凋亡的影响。结果:9种肿瘤细胞均检测到BLT2 mRNA的表达;LY255283明显抑制上述不同肿瘤细胞的增殖,其IC_(50)值分别为0.21、11.17、1.28、5.9、7.9、1.59、0.14、1.25和31.28μmol/L;在1.0和10.0μmol/L两个作用浓度,LY255283诱导MCF7细胞凋亡的发生率分别为20.47%和37.47%,均明显高于空白对照组(8.66%)和DMSO溶剂对照组(11.71%)(P均<0.01)。结论:BLT2在9种人源肿瘤细胞均有表达,其特异拮抗剂LY255283具有抑制肿瘤细胞增殖效应,诱导细胞凋亡可能是其抗肿瘤的机制之一。 OBJECTIVE:To study the inhibition effect of LY255283,a BLT2 receptor antagonist,on different human cancer cell lines.METHODS:The expressions of BLT2 receptor in SMMC7721、A549、Bel7402、BGC823、Eca109、HeLa、HL60、MCF7 and Pc3 cell were evaluated by RT-PCR.The inhibition effect of LY255283 on the nine tumor cell lines was analyzed by MTT assay.Apoptotic cells were evaluated by flow cytometry and fluorescence microscopy.RESULTS:All nine tumor cell lines expressed BLT2 receptors.LY255283 inhibited the proliferation of all nine tumor cell lines,the IC_(50) values were 0.21,11.17,1.28,5.9,7.9,1.59,0.14,1.25 and 31.28μmol/L, respectively.The apoptotic rates of MCF-7 cells induced by LY255283 at 1 and 10μmol/L were 20.47%and 31.28%,respectively,which were significantly increased compared with blank control group(8.66%) and DMSO control group(11.71%)(P0.01).CONCLUSION:BLT2 receptor was expressed in nine human tumor cell lines,and the specific antagonist LY255283 could inhibit the proliferation of tumor cells probably by inducing apoptosis.
出处 《癌变.畸变.突变》 CAS CSCD 2011年第4期298-301,305,共5页 Carcinogenesis,Teratogenesis & Mutagenesis
基金 国家自然科学基金项目(81000784)
关键词 白三烯B4 BLT2 LY255283 肿瘤细胞 leukotriene B4 BLT2 LY255283 tumor cells
  • 相关文献

参考文献17

  • 1Yokomizo T, Masuda K, Kato K, et al. Leukotriene B4 receptor cloning and intracellular signaling [J]. Am J Respir Crit Care Med, 2000, 161 (Sup2): 51-55.
  • 2Kato K, Yokomizo T, Izumi T, et al. Cell-specific transcriptional regulation of human leukotriene B (4) receptor gene [J]. J Exp Med, 2000, 192(3): 413-420.
  • 3Yokomizo T, Kato K, Terawaki K, et al. A second leukotriene B (4) receptor, BLT2: A new therapeutic target in inflammation and immunological disorders [J]. J Exp Med, 2000, 192 (3): 421--432.
  • 4Okomizo T, Izumi T, Shimizu T. Co-expression of two LTB4 receptors in human mononuelear cells [J]. Life Sci, 2001, 68 (19/20): 2207-2212.
  • 5Hicks A, Monkarsh SP, Hoffman AF, et al. Leukotriene B4 receptor antagonists as therapeutics for inflammatory disease: preclinical and clinical developments [J]. Expert Opin Investig Drugs, 2007, 16(12): 1909-1920.
  • 6Hennig R, Osman T, Esposito I, et al. BLT2 is expressed in PanINs, IPMNs, pancreatic cancer and stimulates tumour cell proliferation [J]. BrJ Cancer, 2008, 99 (7): 1064-1073.
  • 7Chen X, Wang S, Wu N, et al. Leukotriene A4 hydrolase as a target for cancer prevention and therapy [J]. Curr Cancer Drug Targets, 2004, 4 (3): 267-283.
  • 8Yoo MH, Song H, Woo CH, et al. Role of the BLT2, leukotriene B4 receptor, in Ras transformation [J]. Oncogene, 2004, 23 (57): 9259-9268.
  • 9Ghosh J, Myers CE. Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells [J]. Proc Natl Acad Sci USA, 1998, 95 (22): 13182-131827.
  • 10Dingzhi Wang, Raymond N. Eicosanoids and cancer [J]. Nat RevCancer, 2010, 10(3): 181-193.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部